1
|
Wang C, Jin Y, Wang J, Zheng K, Lei A, Lu C, Wang S, Wu Y. Protective Immunity against Chlamydia psittaci Lung Infection Induced by a DNA Plasmid Vaccine Carrying CPSIT_p7 Gene Inhibits Dissemination in BALB/c Mice. Int J Mol Sci 2023; 24:ijms24087013. [PMID: 37108176 PMCID: PMC10138700 DOI: 10.3390/ijms24087013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 03/24/2023] [Accepted: 03/25/2023] [Indexed: 04/29/2023] Open
Abstract
Chlamydia psittaci (C. psittaci), a zoonotic pathogen, poses a potential threat to public health security and the development of animal husbandry. Vaccine-based preventative measures for infectious diseases have a promising landscape. DNA vaccines, with many advantages, have become one of the dominant candidate strategies in preventing and controlling the chlamydial infection. Our previous study showed that CPSIT_p7 protein is an effective candidate for a vaccine against C. psittaci. Thus, this study evaluated the protective immunity of pcDNA3.1(+)/CPSIT_p7 against C. psittaci infection in BALB/c mice. We found that pcDNA3.1(+)/CPSIT_p7 can induce strong humoral and cellular immune responses. The IFN-γ and IL-6 levels in the infected lungs of mice immunized with pcDNA3.1(+)/CPSIT_p7 reduced substantially. In addition, the pcDNA3.1(+)/CPSIT_p7 vaccine diminished pulmonary pathological lesions and reduced the C. psittaci load in the lungs of infected mice. It is worth noting that pcDNA3.1(+)/CPSIT_p7 suppressed C. psittaci dissemination in BALB/c mice. In a word, these results demonstrate that the pcDNA3.1(+)/CPSIT_p7 DNA vaccine has good immunogenicity and immunity protection effectiveness against C. psittaci infection in BALB/c mice, especially pulmonary infection, and provides essential practical experience and insights for the development of a DNA vaccine against chlamydial infection.
Collapse
Affiliation(s)
- Chuan Wang
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| | - Yingqi Jin
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| | - Jiewen Wang
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| | - Kang Zheng
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
- Department of Clinical Laboratory, Hengyang Central Hospital, Hengyang 421001, China
| | - Aihua Lei
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| | - Chunxue Lu
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| | - Shuzhi Wang
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
- Department of Pharmacology, School of Pharmaceutical Science, Hengyang Medical College, University of South China, Hengyang 421001, China
| | - Yimou Wu
- Institute of Pathogenic Biology, School of Basic Medicine, Hengyang Medical College, University of South China, Hengyang 421001, China
- Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang 421001, China
| |
Collapse
|
2
|
Zuo Z, Zou Y, Li Q, Guo Y, Zhang T, Wu J, He C, Eko FO. Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge. Sci Rep 2021; 11:10389. [PMID: 34001988 PMCID: PMC8129140 DOI: 10.1038/s41598-021-89940-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 05/04/2021] [Indexed: 02/03/2023] Open
Abstract
Vaccines based on live attenuated Chlamydia elementary bodies (EBs) can cause disease in vaccinated animals and the comparably safer inactivated whole EBs are only marginally protective. Recent studies show that a vaccine formulation comprising UV-inactivated EBs (EB) and appropriate mucosal delivery systems and/or adjuvants induced significant protective immunity. We tested the hypothesis that intranasal delivery of UV-inactivated C. psittaci EB formulated in Vibrio cholerae ghosts (VCG)-chitosan nanoparticles will induce protective immunity against intranasal challenge in SPF chickens. We first compared the impact of VCG and CpG adjuvants on protective immunity following IN mucosal and IM systemic delivery of EB formulated in chitosan hydrogel/microspheres. Immunologic analysis revealed that IN immunization in the presence of VCG induced higher levels of IFN-γ response than IM delivery or the CpG adjuvanted groups. Also, vaccine efficacy evaluation showed enhanced pharyngeal bacterial clearance and protection against lung lesions with the VCG adjuvanted vaccine formulation, thereby establishing the superior adjuvanticity of VCG over CpG. We next evaluated the impact of different concentrations of VCG on protective immunity following IN mucosal immunization. Interestingly, the adjuvanticity of VCG was concentration-dependent, since protective immunity induced following IN mucosal immunization showed dose-dependent immune responses and protection. These studies reveal that formulation of inactivated chlamydial antigens with adjuvants, such as VCG and chitosan increases their ability to induce protective immune responses against challenge.
Collapse
Affiliation(s)
- Zonghui Zuo
- grid.22935.3f0000 0004 0530 8290Key Lab of Animal Epidemiology and Zoonosis, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 People’s Republic of China
| | - Yongjuan Zou
- grid.9227.e0000000119573309Key Laboratory of Biopharmaceutical Production and Formulation Engineering, Chinese Academy of Sciences, Beijing, 100049 People’s Republic of China
| | - Qiang Li
- grid.22935.3f0000 0004 0530 8290Key Lab of Animal Epidemiology and Zoonosis, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 People’s Republic of China
| | - Yongxia Guo
- grid.22935.3f0000 0004 0530 8290Key Lab of Animal Epidemiology and Zoonosis, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 People’s Republic of China
| | - Tianyuan Zhang
- grid.22935.3f0000 0004 0530 8290Key Lab of Animal Epidemiology and Zoonosis, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 People’s Republic of China
| | - Jie Wu
- grid.9227.e0000000119573309Key Laboratory of Biopharmaceutical Production and Formulation Engineering, Chinese Academy of Sciences, Beijing, 100049 People’s Republic of China
| | - Cheng He
- grid.22935.3f0000 0004 0530 8290Key Lab of Animal Epidemiology and Zoonosis, College of Veterinary Medicine, China Agricultural University, Beijing, 100193 People’s Republic of China
| | - Francis O. Eko
- grid.9001.80000 0001 2228 775XDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310 USA
| |
Collapse
|
3
|
Liu S, Sun W, Huang X, Zhang W, Jia C, Luo J, Shen Y, El-Ashram S, He C. A Promising Recombinant Herpesvirus of Turkeys Vaccine Expressing PmpD-N of Chlamydia psittaci Based on Elongation Factor-1 Alpha Promoter. Front Vet Sci 2017; 4:221. [PMID: 29376059 PMCID: PMC5763144 DOI: 10.3389/fvets.2017.00221] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2017] [Accepted: 12/04/2017] [Indexed: 12/02/2022] Open
Abstract
The obligate intracellular Gram-negative bacterium Chlamydia psittaci often causes avian chlamydiosis and influenza-like symptoms in humans. However, the commercial subunit C. psittaci vaccine could only provide a partial protection against avian chlamydiosis due to poor cellular immune response. In our previous study, a recombinant herpesvirus of turkeys (HVT)-delivered vaccine against C. psittaci and Marek’s disease based on human cytomegalovirus (CMV) promoter (rHVT-CMV-pmpD) was developed and provided an effective protection against C. psittaci disease with less lesions and reduced chlamydial loads. In this study, we developed another recombinant HVT vaccine expressing the N-terminal fragment of PmpD (PmpD-N) based on human elongation factor-1 alpha (EF-1α) promoter (rHVT-EF-pmpD) by modifying the HVT genome within a bacterial artificial chromosome. The related characterization of rHVT-EF-pmpD was evaluated in vitro in comparison with that of rHVT-CMV-pmpD. The expression of PmpD-N was determined by western blot. Under immunofluorescence microscopy, PmpD-N protein of both two recombinant viruses was located in the cytoplasm and on the cell surface. Growth kinetics of rHVT-EF-pmpD was comparable to that of rHVT-CMV-pmpD, and the growth rate of rHVT-EF-pmpD was apparently higher than that of rHVT-CMV-pmpD on 48, 72, and 120 h postinfection. Macrophages activated by rHVT-EF-pmpD could produce more nitric oxide and IL-6 than that activated by rHVT-CMV-pmpD. In this study, a recombinant HVT vaccine expressing PmpD-N based on EF-1α promoter was constructed successfully, and a further research in vivo was needed to analyze the vaccine efficacy.
Collapse
Affiliation(s)
- Shanshan Liu
- Tongren Polytechnic College, Tongren, China.,National and Local Engineering Research Centre for Separation and Purification Ethnic Chinese Veterinary Herbs, Tongren, China.,Key Lab of Animal Epidemiology and Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China
| | - Wei Sun
- Tongren Polytechnic College, Tongren, China.,Key Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Wenjiang, China
| | | | - Wen Zhang
- Tongren Polytechnic College, Tongren, China.,National and Local Engineering Research Centre for Separation and Purification Ethnic Chinese Veterinary Herbs, Tongren, China
| | - Changqing Jia
- Tongren Polytechnic College, Tongren, China.,National and Local Engineering Research Centre for Separation and Purification Ethnic Chinese Veterinary Herbs, Tongren, China
| | - Jie Luo
- Tongren Polytechnic College, Tongren, China.,National and Local Engineering Research Centre for Separation and Purification Ethnic Chinese Veterinary Herbs, Tongren, China
| | - Yihua Shen
- Tongren Polytechnic College, Tongren, China
| | - Saeed El-Ashram
- School of Life Science and Engineering, Foshan University, Guangdong, China
| | - Cheng He
- Key Lab of Animal Epidemiology and Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing, China
| |
Collapse
|
4
|
Meunier M, Chemaly M, Dory D. DNA vaccination of poultry: The current status in 2015. Vaccine 2015; 34:202-211. [PMID: 26620840 PMCID: PMC7115526 DOI: 10.1016/j.vaccine.2015.11.043] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Revised: 11/05/2015] [Accepted: 11/12/2015] [Indexed: 01/13/2023]
Abstract
Poultry DNA vaccination studies are regularly being published since 1993. These studies are mainly, but not only, concerned with vaccination against viruses. The different strategies of improving DNA vaccine efficacies are presented. The fate of the vaccine plasmid, immune properties and other applications are described. Despite the compiling preclinical reports, a poultry DNA vaccine is yet unavailable in the market.
DNA vaccination is a promising alternative strategy for developing new human and animal vaccines. The massive efforts made these past 25 years to increase the immunizing potential of this kind of vaccine are still ongoing. A relatively small number of studies concerning poultry have been published. Even though there is a need for new poultry vaccines, five parameters must nevertheless be taken into account for their development: the vaccine has to be very effective, safe, inexpensive, suitable for mass vaccination and able to induce immune responses in the presence of maternal antibodies (when appropriate). DNA vaccination should meet these requirements. This review describes studies in this field performed exclusively on birds (chickens, ducks and turkeys). No evaluations of avian DNA vaccine efficacy performed on mice as preliminary tests have been taken into consideration. The review first describes the state of the art for DNA vaccination in poultry: pathogens targeted, plasmids used and different routes of vaccine administration. Second, it presents strategies designed to improve DNA vaccine efficacy: influence of the route of administration, plasmid dose and age of birds on their first inoculation; increasing plasmid uptake by host cells; addition of immunomodulators; optimization of plasmid backbones and codon usage; association of vaccine antigens and finally, heterologous prime-boost regimens. The final part will indicate additional properties of DNA vaccines in poultry: fate of the plasmids upon inoculation, immunological considerations and the use of DNA vaccines for purposes other than preventing infectious diseases.
Collapse
Affiliation(s)
- Marine Meunier
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Viral Genetics and Biosafety Unit, Ploufragan, France; French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Unit of Hygiene and Quality of Poultry and Pork Products, Ploufragan, France
| | - Marianne Chemaly
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Unit of Hygiene and Quality of Poultry and Pork Products, Ploufragan, France
| | - Daniel Dory
- French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Ploufragan/Plouzané Laboratory, Viral Genetics and Biosafety Unit, Ploufragan, France.
| |
Collapse
|
5
|
Construction of Recombinant HVT Expressing PmpD, and Immunological Evaluation against Chlamydia psittaci and Marek's Disease Virus. PLoS One 2015; 10:e0124992. [PMID: 25893439 PMCID: PMC4404326 DOI: 10.1371/journal.pone.0124992] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Accepted: 03/11/2015] [Indexed: 11/19/2022] Open
Abstract
Chlamydia psittaci (C. psittaci) is an obligate intracellular zoonotic pathogen that can be transmitted to humans from birds. No efficacious commercial vaccine is available for clearing chlamydial infection due to lack of potential vaccine candidates and effective delivery vehicles. Herpesvirus of turkeys (HVT) is an efficacious commercially available vaccine against Marek’s Disease virus (MDV). In this study, a recombinant HVT-delivered vaccine against C. psittaci and Marek’s disease was developed and examined. The 5'-terminus of pmpD gene (pmpD-N) encoding the N-terminal fragment of polymorphic membrane protein D of C. psittaci was inserted into a nonessential region of HVT genome using reverse genetics based on an infectious bacterial artificial chromosome (BAC) clone of HVT. The recombinant virus (rHVT-pmpD-N) was recovered from primary chicken embryo fibroblast (CEF) cells by transfection of modified HVT BAC DNA containing the pmpD-N gene. The rHVT-pmpD-N construct was confirmed to express PmpD-N by immunoblot and immunofluorescence. The rHVT-pmpD-N was stable during 20 passages in vitro. The growth kinetics of rHVT-pmpD-N was comparable to that of parental HVT in vitro and in vivo. One-day-old SPF chickens inoculated subcutaneously with rHVT-pmpD-N displayed increased PmpD-specific antibody levels and a vigorous PmpD-specific lymphocyte proliferation response using HVT vector or CEF cells as control. Furthermore, the percentage of CD4+ cells was significantly elevated in rHVT-pmpD-N-immunized birds as compared to the parental HVT. All chickens vaccinated with rHVT-pmpD-N or parental HVT were protected completely against challenge with a very virulent strain of Marek’s Disease virus (MDV) RB-1B. Post challenge with C. psittaci CB7 strain, a significant decrease in respiratory distress, lesions and Chlamydia load was found in the rHVT-pmpD-N-vaccinated group compared to the parental HVT. In conclusion, our study suggests that the rHVT-pmpD-N live vaccine may be viable as a candidate dual vaccine that provides protection against both very virulent MDV and C. psittaci.
Collapse
|
6
|
Ou C, Tian D, Ling Y, Pan Q, He Q, Eko FO, He C. Evaluation of an ompA-based phage-mediated DNA vaccine against Chlamydia abortus in piglets. Int Immunopharmacol 2013; 16:505-10. [PMID: 23669337 DOI: 10.1016/j.intimp.2013.04.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Revised: 04/20/2013] [Accepted: 04/23/2013] [Indexed: 11/29/2022]
Abstract
Chlamydia abortus (C. abortus) is an obligate intracellular pathogen that causes abortion in pigs and poses a zoonotic risk in pregnant women. Although attenuated and inactivated vaccines are available, they do not provide complete protection in animals underlining the need to develop new vaccines. In this study, we tested the hypothesis that intramuscular immunization with an ompA-based phage-mediated DNA chlamydial vaccine candidate will induce significant antigen-specific cellular and humoral immune responses. Thus, groups of piglets (five per group) were immunized intramuscularly with the phage-MOMP vaccine (λ-MOMP) or a commercial live-attenuated vaccine (1B vaccine) or a GFP-expressing phage (λ-GFP) or phosphate buffered saline (PBS) (control) and antigen-specific cell-mediated and humoral immune responses were evaluated. By day 63 post-immunization, the λ-MOMP vaccine elicited significantly higher (P<0.05) levels of antigen-specific serum IgG antibody responses than the 1B vaccine or control did. Also, piglets immunized with λ-MOMP vaccine had significantly higher (P<0.05) MOMP-specific lymphocyte proliferative responses compared to those immunized with the 1B vaccine or control. Furthermore, the total T-cell numbers (CD3+) and the proportion of CD4+ and CD8+ T-cell subsets as well as the ratio of CD4+/CD8+ T cells elicited following immunization were comparable between the λ-MOMP- and 1B-vaccinated animals on both days 63 and 70. Interestingly, although the proportion of CD3+CD4-CD8- double negative T cells on day 63 was significantly higher (P<0.05) in the 1B vaccine group compared to the λ-MOMP-immunized group, there was a significant decrease in the proportion of this T-cell population on day 70 in the 1B compared to the λ-MOMP vaccinated group. These results indicate that the λ-MOMP DNA vaccine is capable of inducing antigen-specific cellular and humoral immune responses that may provide protective immunity against a live challenge infection with C. abortus.
Collapse
Affiliation(s)
- Changbo Ou
- Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Beijing 100094, China
| | | | | | | | | | | | | |
Collapse
|
7
|
Zhang XX, Yu H, Wang XH, Li XZ, Zhu YP, Li HX, Luo SJ, Yuan ZG. Protective efficacy against Chlamydophila psittaci by oral immunization based on transgenic rice expressing MOMP in mice. Vaccine 2012. [PMID: 23196208 DOI: 10.1016/j.vaccine.2012.11.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Avian chlamydiosis is caused by Chlamydophila psittaci (Cp. psittaci) and major outer membrane protein (MOMP) of Cp. psittaci is an excellent vaccine candidate. In this study, the MOMP gene was expressed in rice callus by the Agrobacterium tumefaciens vector. The production of protein in transgenic rice seeds was confirmed and quantified by Western-blot and ELISA, the results demonstrating that the antigen was expressed stably. The transgenic rice seeds expressing the MOMP protein were administered by the oral route to BALB/c mice, which developed MOMP-specific serum IgG and fecal IgA antibodies and a splenocyte MOMP-specific proliferative response and significant levels of IFN-γ, IL-2, IL-4, IL-5 and TGF-β production. Immunization with MOMP transgenic seeds induced partial protection (50%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain. Lung function after challenge was less affected compared non-MOMP immunized animals. The results demonstrate the feasibility of using transgenic rice seeds as an oral vaccine to generate protective immunity and reduce the lung lesions in mice against virulent Cp. psittaci 6BC strain. This finding has implications for further development of an oral vaccine against avian chlamydiosis.
Collapse
Affiliation(s)
- Xiu-Xiang Zhang
- College of Agriculture, South China Agricultural University, Tianhe District, Guangzhou 510642, Guangdong Province, PR China
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Schautteet K, De Clercq E, Jönsson Y, Lagae S, Chiers K, Cox E, Vanrompay D. Protection of pigs against genital Chlamydia trachomatis challenge by parenteral or mucosal DNA immunization. Vaccine 2012; 30:2869-81. [DOI: 10.1016/j.vaccine.2012.02.044] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 02/14/2012] [Accepted: 02/17/2012] [Indexed: 01/06/2023]
|
9
|
Ling Y, Liu W, Clark JR, March JB, Yang J, He C. Protection of mice against Chlamydophila abortus infection with a bacteriophage-mediated DNA vaccine expressing the major outer membrane protein. Vet Immunol Immunopathol 2011; 144:389-95. [DOI: 10.1016/j.vetimm.2011.08.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2009] [Revised: 07/19/2011] [Accepted: 08/02/2011] [Indexed: 10/17/2022]
|
10
|
Protection of pigs against Chlamydia trachomatis challenge by administration of a MOMP-based DNA vaccine in the vaginal mucosa. Vaccine 2011; 29:1399-407. [DOI: 10.1016/j.vaccine.2010.12.042] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Revised: 11/30/2010] [Accepted: 12/14/2010] [Indexed: 11/23/2022]
|
11
|
Schautteet K, Stuyven E, Cox E, Vanrompay D. Validation of the Chlamydia trachomatis genital challenge pig model for testing recombinant protein vaccines. J Med Microbiol 2011; 60:117-127. [DOI: 10.1099/jmm.0.024448-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Chlamydia trachomatis is a Gram-negative obligate intracellular bacterial pathogen that is the leading cause of bacterial sexually transmitted disease in humans in developing countries. A vaccination programme is considered to be the best approach to reduce the prevalence of C. trachomatis infections. However, there are still no commercial C. trachomatis vaccines. In order to develop effective C. trachomatis vaccines, it is important to identify those antigens that elicit a protective immune response, and to develop new and adequate methods and adjuvants for effective vaccine delivery, as conventional methods have failed to induce protective immunity. In order to test different vaccine candidates, animal models are needed. Former studies have used non-primate monkeys, mice or guinea pig infection models. The present study used a pig model for testing recombinant protein vaccines. Two recombinant proteins, polymorphic membrane protein G (PmpG), and secretion and cellular translocation protein C (SctC), were tested for their ability to create protection in a pig C. trachomatis challenge model. The vaccines were administered subcutaneously with GNE adjuvant. Six weeks later, animals were challenged intravaginally with C. trachomatis serovar E. After a further 4 weeks, the pigs were euthanized. PmpG-immunized pigs were better protected than pigs immunized with the less promising SctC candidate vaccine antigen. Interestingly, significant protection was apparently not correlated with a strong humoral immune response upon subcutaneous immunization. In conclusion, the pig model is useful for studying the efficacy of vaccine candidates against genital human C. trachomatis infection.
Collapse
Affiliation(s)
- Katelijn Schautteet
- Laboratory of Immunology and Animal Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| | - Edith Stuyven
- Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium
| | - Eric Cox
- Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium
| | - Daisy Vanrompay
- Laboratory of Immunology and Animal Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| |
Collapse
|
12
|
Ling Y, Li S, Yang J, Yuan J, He C. Co-administration of the polysaccharide of Lycium barbarum with DNA vaccine of Chlamydophila abortus augments protection. Immunol Invest 2010; 40:1-13. [PMID: 20942772 DOI: 10.3109/08820139.2010.504803] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Lycium barbarum polysaccharides (LBP) can stimulate moderate immune responses therefore could potentially be used as a substitute for oil adjuvants in veterinary vaccines. In the present study, it was shown that the isolated active component of LBP3a, combined with a DNA vaccine encoding the major outer membrane protein (MOMP) of Chlamydophila abortus, induced protection in mice against challenge. Sixty BALB/c mice were randomly assigned to 5 groups. Sub-fractions of polysaccharide LBP3a, at 12.5, 25 and 50 mg/kg concentrations, respectively, were mixed with a pCI-neo::MOMP (pMOMP) vaccine. Mice administrated with pCI-neo + LBP3a were served as a control. All mice were inoculated at day 0, 14, and 28, and challenged on day 44. The effects of LBp3a on serum antibody levels, in vitro lymphocyte proliferation, the activity of interleaukin-2 (IL-2), interferon-γ (IFN-γ), tumor necrosis factor α(TNF-α)and chlamydia clearance were determined. A combination of DNA vaccine and LBP3a induced significantly higher antibody levels in mice, higher T cell proliferation and higher levels of IFN-γ and IL-2. Mice immunized with DNA and LBP3a also showed significantly higher levels of chlamydia clearance in mice spleens and a greater Th1 immune response. The immunoenhancement induced by 25 mg/kg LBP3a is more effective than that induced by a 12.5 and 50 mg/kg. This implies that LBP3a at 25 mg/kg has a high potential to be used as an effective adjuvant with a DNA vaccine against swine Chlamydophila abortus.
Collapse
Affiliation(s)
- Yong Ling
- Key Lab of Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, China Agricultural University, Haidian District, Beijing 100193, China
| | | | | | | | | |
Collapse
|
13
|
Verminnen K, Beeckman DSA, Sanders NN, De Smedt S, Vanrompay DCG. Vaccination of turkeys against Chlamydophila psittaci through optimised DNA formulation and administration. Vaccine 2010; 28:3095-105. [PMID: 20199760 DOI: 10.1016/j.vaccine.2010.02.064] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 01/28/2010] [Accepted: 02/15/2010] [Indexed: 01/11/2023]
Abstract
We have demonstrated that vaccination of turkeys with an unformulated DNA vaccine induces significant protection against Chlamydophila (Cp.) psittaci infections. Nevertheless, the immunogenicity of the DNA vaccine can still be improved by increasing translation and transfection efficiency. Therefore, the ompA codon was adapted to the codon usage in birds, resulting in pcDNA1/MOMP(opt). To increase gene transfer, polyplexes of pcDNA1/MOMP(opt)-EGFP with different cationic polymers, such as linear and branched polyethyleneimine (lPEI and brPEI) and starburst PAMAM dendrimers, and lipoplexes with cationic DOTAP/DOPE liposomes were created. Transfection of lPEI and brPEI polyplexes with an N/P ratio of 8 resulted in the highest transfection efficiencies, but lPEI polyplexes were completely destroyed following nebulisation. Secondly, we examined the capacity of nebulised or intramuscularly (IM) administered brPEI-pcDNA1/MOMP(opt) to induce a significant protective immune response in SPF turkeys experimentally infected with 10(8) TCID(50) of a virulent Cp. psittaci strain. Results were compared to IM administration of naked plasmid DNA and to results of non-vaccinated animals. Intramuscular administration of brPEI-pcDNA1/MOMP(opt) increased the immunogenicity of the Cp. psittaci DNA vaccine as compared to IM administration of pcDNA1/MOMP(opt) or aerosol delivery of brPEI-pcDNA1/MOMP(opt). Improved immunogenicity was correlated with increased protection. Vaccinated groups were significantly protected against Cp. psittaci challenge.
Collapse
Affiliation(s)
- Kristel Verminnen
- Department of Molecular Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| | | | | | | | | |
Collapse
|
14
|
Savy M, Edmond K, Fine PEM, Hall A, Hennig BJ, Moore SE, Mulholland K, Schaible U, Prentice AM. Landscape analysis of interactions between nutrition and vaccine responses in children. J Nutr 2009; 139:2154S-218S. [PMID: 19793845 DOI: 10.3945/jn.109.105312] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The world's poorest children are likely to be malnourished when receiving their childhood vaccines. It is uncertain whether this affects vaccine efficacy and whether the coadministration of nutrient supplements with vaccines has beneficial or detrimental effects. More recently, a detrimental interaction between vitamin A (VA) supplementation (VAS) and the killed diphtheria-tetanus-pertussis vaccine given in early childhood has been suggested. This report provides a critical review of the published interactions between nutritional status and/or supplementation and vaccine responses in children. Due to an absence of evidence for most nutrients, this analysis focused on protein-energy, vitamins A and D, and iron and zinc. All vaccines were considered. Both observational studies and clinical trials that led to peer-reviewed publications in English or French were included. These criteria led to a pool of 58 studies for protein-energy malnutrition, 43 for VA, 4 for vitamin D, 10 for iron, and 22 for zinc. Our analysis indicates that malnutrition has surprisingly little or no effect on vaccine responses. Evidence for definitive adjunctive effects of micronutrient supplementation at the time of vaccination is also weak. Overall, the paucity, poor quality, and heterogeneity of data make it difficult to draw firm conclusions. The use of simple endpoints that may not correlate strongly with disease protection adds uncertainty. A detailed examination of the immunological mechanisms involved in potential interactions, employing modern methodologies, is therefore required. This would also help us understand the proposed, but still unproven, negative interactions between VAS and vaccine safety, a resolution of which is urgently required.
Collapse
Affiliation(s)
- Mathilde Savy
- Medical Research Council International Nutrition Group, London School of Hygiene and Tropical Medicine, London, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Harkinezhad T, Schautteet K, Vanrompay D. Protection of budgerigars (Melopsittacus undulatus) against Chlamydophila psittaci challenge by DNA vaccination. Vet Res 2009; 40:61. [PMID: 19640395 DOI: 10.1051/vetres/2009044] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2009] [Accepted: 07/29/2009] [Indexed: 11/14/2022] Open
Abstract
Plasmid DNA (pcDNA1::MOMP A) expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci genotype A strain 89/1051 has been tested for its ability to induce protective immunity against Cp. psittaci challenge in budgerigars. Eight pairs of male and female budgerigars were housed in eight separate bird cages placed in two negative pressure isolators, four cages per group. All budgerigars were immunised twice intramuscularly with 100 microasmid DNA. Both groups received a primary DNA inoculation at day 0 followed by a booster inoculation 3 weeks later. Group 1 received pcDNA1::MOMP A, while group 2 received the placebo vaccine pcDNA1. Budgerigars were challenged by aerosol 2 weeks following the booster vaccination. The challenge consisted of 10(8) TCID(50) of the homologous Cp. psittaci genotype A strain. Cloacal and pharyngeal swabs of all budgerigars, taken prior to the experimental infection were negative in both PCR and culture. However, all budgerigars showed low pre-existing serum antibody titres. This indicates that animals were previously infected. Nevertheless, DNA immunisation could significantly reduce clinical signs, macroscopic lesions, pharyngeal and cloacal excretion as well as chlamydial replication, even in the presence of pre-existing serum antibodies, as compared to the placebo-vaccinated controls.
Collapse
Affiliation(s)
- Taher Harkinezhad
- Department of Molecular Biotechnology, Ghent University, Faculty of Bioscience Engineering, Coupure Links 653, 9000 Ghent, Belgium
| | | | | |
Collapse
|
16
|
Mucosal immunity in mice induced by orally administered transgenic rice. Vaccine 2009; 27:1596-600. [PMID: 19146896 DOI: 10.1016/j.vaccine.2008.12.042] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2008] [Revised: 12/07/2008] [Accepted: 12/20/2008] [Indexed: 11/21/2022]
Abstract
Transgenic plants are efficient means of producing and delivering oral vaccines. Rice material shown previously to express the Chlamydophila psittaci (Cp. psittaci) antigen (MOMP) fused to the B subunit of Escherichia coli heat-labile enterotoxin (LTB) was fed to mice and the resulting immune response was investigated. Oral immunization of mice with the transgenic rice elicited MOMP-specific sera IgG and IgA antibodies, a strong increase of the lymphoproliferative response, and significant levels of IFN-gamma, TGF-beta and IL-2 production. Furthermore, the immunization of mice with transgenic rice elicited strong cytotoxic T lymphocyte (CTL) responses in vitro. These results demonstrated that plant-made LTB-MOMP fusion protein could induce significant humoral and cellular Th1 and Th3 immune responses. Moreover, transgenic rice immunization induced partial protection (53.3%) against a lethal challenge with the highly virulent Cp. psittaci 6BC strain in a BALB/c mouse model. These results suggest that expression of protective antigens of Cp. psittaci in transgenic rice has potential as an edible vaccine against avain chlamydiosis.
Collapse
|
17
|
Zhang F, Li S, Yang J, Yang L, He C. Induction of a protective immune response against swine Chlamydophila abortus infection in mice following co-vaccination of omp-1 DNA with recombinant MOMP. Zoonoses Public Health 2008; 56:71-6. [PMID: 18721226 DOI: 10.1111/j.1863-2378.2008.01160.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Chlamydophila abortus is the causative agent of abortion in pigs and pregnant women. Seroconversion rates were arranged from 11% to 80% in piglets and sows in China. These very high rates illustrate the scale of the problem in China and highlight the urgent need for the development of a C. abortus vaccine. An efficacious anti-chlamydial vaccine should induce not only strong mucosal and systemic T-helper type 1 (Th1) immune response but also give a humoral response that enhances Th1 activation following infection. In order to evaluate an active immune response of a combination of the major outer membrane protein (MOMP) DNA- and protein-based vaccines, 54 BALB/c mice were randomly assigned to six groups and inoculated intramuscularly with: (i) 100 microg pcDNA::MOMP, (ii) 10 microg r-MOMP, (iii) primed with 100 microg pcDNA::MOMP and boosted with 10 microg r-MOMP, (iv) primed-boosted with a combination of pcDNA::MOMP and r-MOMP simultaneously, (v) live-attenuated 1B vaccine, (vi) 100 microg pcDNA3.1 vector. All animals were vaccinated two times at 14 days intervals. Results showed that mice given DNA and r-MOMP induced higher antibody levels, higher T cells proliferation and an elevated level of chlamydial clearance in spleen, which was equivalent to the clearance of 1B vaccine. Mice administrated the DNA-primed/MOMP-boosted approach elicited moderate antibody levels, less T-lymphocyte proliferation and lower chlamydial clearance as compared with 1B vaccine. Co-immunization with DNA- and r-MOMP vaccine may provide novel ways for active immunization strategy against swine C. abortus.
Collapse
Affiliation(s)
- F Zhang
- Key Lab of Preventive Veterinary Medicine of Chinese Ministry of Agriculture, China Agricultural University, Beijing, China
| | | | | | | | | |
Collapse
|
18
|
Rao S, Kong WP, Wei CJ, Yang ZY, Nason M, Styles D, DeTolla LJ, Sorrell EM, Song H, Wan H, Ramirez-Nieto GC, Perez D, Nabel GJ. Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 2008; 3:e2432. [PMID: 19293944 PMCID: PMC2657001 DOI: 10.1371/journal.pone.0002432] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2008] [Accepted: 05/02/2008] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Sustained outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in avian species increase the risk of reassortment and adaptation to humans. The ability to contain its spread in chickens would reduce this threat and help maintain the capacity for egg-based vaccine production. While vaccines offer the potential to control avian disease, a major concern of current vaccines is their potency and inability to protect against evolving avian influenza viruses. METHODOLOGY / PRINCIPAL FINDINGS The ability of DNA vaccines encoding hemagglutinin (HA) proteins from different HPAI H5N1 serotypes was evaluated for its ability to elicit neutralizing antibodies and to protect against homologous and heterologous HPAI H5N1 strain challenge in mice and chickens after DNA immunization by needle and syringe or with a pressure injection device. These vaccines elicited antibodies that neutralized multiple strains of HPAI H5N1 when given in combinations containing up to 10 HAs. The response was dose-dependent, and breadth was determined by the choice of the influenza virus HA in the vaccine. Monovalent and trivalent HA vaccines were tested first in mice and conferred protection against lethal H5N1 A/Vietnam/1203/2004 challenge 68 weeks after vaccination. In chickens, protection was observed against heterologous strains of HPAI H5N1 after vaccination with a trivalent H5 serotype DNA vaccine with doses as low as 5 microg DNA given twice either by intramuscular needle injection or with a needle-free device. CONCLUSIONS/SIGNIFICANCE DNA vaccines offer a generic approach to influenza virus immunization applicable to multiple animal species. In addition, the ability to substitute plasmids encoding different strains enables rapid adaptation of the vaccine to newly evolving field isolates.
Collapse
Affiliation(s)
- Srinivas Rao
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Wing-Pui Kong
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Chih-Jen Wei
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Zhi-Yong Yang
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Martha Nason
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Darrel Styles
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Riverdale, Maryland, United States of America
| | - Louis J. DeTolla
- Comparative Medicine, University of Maryland Baltimore, Baltimore, Maryland, United States of America
| | - Erin M. Sorrell
- College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
| | - Haichen Song
- College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
| | - Hongquan Wan
- College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
| | - Gloria C. Ramirez-Nieto
- College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
| | - Daniel Perez
- College of Veterinary Medicine, University of Maryland, College Park, Maryland, United States of America
| | - Gary J. Nabel
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
- * E-mail:
| |
Collapse
|
19
|
Evaluation of a Chlamydophila psittaci infection diagnostic platform for zoonotic risk assessment. J Clin Microbiol 2007; 46:281-5. [PMID: 18003799 DOI: 10.1128/jcm.01153-07] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Reports on zoonotic transmission of Chlamydophila psittaci originating from poultry are incidentally published. During recent studies in European turkeys we isolated C. psittaci genotypes A, B, D, E, F, and E/B, all considered potentially dangerous for humans. This encouraged us to analyze the zoonotic risk on a Belgian turkey farm, from production onset until slaughter, using a Chlamydophila psittaci diagnostic platform. Twenty individually marked hens, as well as the farmer and two scientists, were monitored medically. Bioaerosol monitoring, serology, isolation, and nested PCR demonstrated chlamydiosis on the farm leading to symptomatic psittacosis in all 3 persons involved. ompA sequencing confirmed the zoonotic transmission of C. psittaci genotype A. Strangely, two different antibody microimmunofluorescence (MIF) tests remained negative in all infected persons. The results demonstrate the value of the currently used diagnostic platform in demonstrating C. psittaci infections in both birds and humans but raise questions regarding use of the MIF test for diagnosing human psittacosis. In addition, our results suggest the underestimation of psittacosis in the poultry industry, stressing the need for a veterinary vaccine and recommendations for zoonotic risk reduction strategies.
Collapse
|
20
|
Zhou J, Qiu C, Cao XA, Lin G. Construction and immunogenicity of recombinant adenovirus expressing the major outer membrane protein (MOMP) of Chlamydophila psittaci in chicks. Vaccine 2007; 25:6367-72. [PMID: 17640776 DOI: 10.1016/j.vaccine.2007.06.031] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2006] [Revised: 05/10/2007] [Accepted: 06/10/2007] [Indexed: 10/23/2022]
Abstract
Avian chlamydiosis is caused by Chlamydophila psittaci. The major outer membrane protein (MOMP) encoded by the outer membrane protein 1 (omp1) gene is an excellent candidate for genetic engineering of a vaccine against avian chlamydiosis. In this study, the MOMP gene was amplified by PCR and cloned into the transfer vector pShuttle-CMV. The recombinant plasmid was obtained by recombination between the plasmid pShuttle-CMV-MOMP and skeleton vector pAdEasy-1 in Escherichia coli strain BJ5183. The titer of recombinant adenovirus containing the MOMP gene (rAd-MOMP) of C. psittaci was 3.4x10(10)TCID(50)/ml in human embryonic kidney 293 (HEK293) monolayer cells. The expression of the MOMP in HEK293 cells infected with rAd-MOMP was confirmed by an indirect immunofluorescence assay. Specific pathogen free (SPF) chicks were inoculated with 10(6), 10(8), and 10(10)TCID(50) of rAd-MOMP/chick. Inoculated chicks generated antibodies against MOMP of C. psittaci, which were detected by an indirect hemagglutination test (IHA). The vaccinated chicks were challenged with a virulent Chinese field isolate. Nine out of 10 chicks in the vaccinated group were protected, while birds in the wild-type adenovirus control group and the PBS control group all showed clinical signs after challenge. The results indicate that the recombinant adenovirus containing the MOMP gene of C. psittaci might be a candidate vaccine against avian chlamydiosis.
Collapse
Affiliation(s)
- Jizhang Zhou
- Key Laboratory of Animal Virology of Ministry of Agriculture, State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
| | | | | | | |
Collapse
|
21
|
Enioutina EY, Bareyan D, Daynes RA. Vitamin D3-mediated alterations to myeloid dendritic cell trafficking in vivo expand the scope of their antigen presenting properties. Vaccine 2006; 25:1236-49. [PMID: 17092617 DOI: 10.1016/j.vaccine.2006.10.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2006] [Revised: 09/22/2006] [Accepted: 10/05/2006] [Indexed: 01/23/2023]
Abstract
The mucosal immune system provides the host with a first line of adaptive immune defense against invasion by many species of pathogenic microorganisms and their secreted products. Calcitriol, the active form of Vitamin D3 (VD3), promotes the induction of mucosal immunity in mice when added to subcutaneously administered vaccine formulations. Dendritic cells (DCs) activated at vaccination sites where VD3 is present gain the capacity to bypass sequestration in the draining lymph node and traffic to the Peyer's Patches (PP) of immunized animals. By employing protocols that allow the effective tracking of endogenous or adoptively transferred myeloid DCs in vivo, we found that VD3 influences on the trafficking of fully differentiated immature DCs were temporary, and occur without negative effects to antigen processing or peptide presentation to CD4+ T cells. In contrast, DCs differentiated from hematopoietic precursors in the presence of VD3 (conditioned DCs), were markedly compromised in their antigen presenting properties, while manifesting clear alterations to their trafficking properties in vivo. Similar to the recent finding of VD3-mediated enhancement of innate immune protection, our findings suggest that VD3 could also play an important role in controlling the types of immune effector responses elicited subsequent to either infection or vaccination.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Animals
- Antigen Presentation/drug effects
- Antigen Presentation/immunology
- Bone Marrow Cells/immunology
- CD4-Positive T-Lymphocytes/immunology
- Chemotaxis, Leukocyte/immunology
- Cholecalciferol/pharmacology
- Dendritic Cells/drug effects
- Dendritic Cells/immunology
- Female
- Immunity, Mucosal/immunology
- Immunotherapy, Adoptive
- Lymphoid Tissue/immunology
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C3H
- Mice, Transgenic
- Myeloid Cells/drug effects
- Myeloid Cells/immunology
- Receptors, CCR7
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Skin/cytology
- Skin/immunology
Collapse
Affiliation(s)
- Elena Y Enioutina
- Department of Pathology, University of Utah Medical School, 30 North 1900 East, Salt Lake City, UT 84132, USA.
| | | | | |
Collapse
|
22
|
Loots K, Vleugels B, Ons E, Vanrompay D, Goddeeris BM. Evaluation of the persistence and gene expression of an anti-Chlamydophila psittaci DNA vaccine in turkey muscle. BMC Vet Res 2006; 2:18. [PMID: 16764710 PMCID: PMC1524740 DOI: 10.1186/1746-6148-2-18] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2006] [Accepted: 06/09/2006] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND DNA vaccination has been shown to elicit specific cellular and humoral immune responses to many different agents in a broad variety of species. However, looking at a commercial use, the duration of the immune response against the vaccine is critical. Therefore the persistence of the DNA vaccine, as well as its expression, should be investigated. We conducted these investigations on a DNA vaccine against Chlamydophila psittaci, a Gram-negative intracellular bacterium which causes respiratory disease in turkeys and humans. Previous studies showed that the DNA vaccine confers partial protection against C. psittaci infection in turkeys. Turkeys were injected intramuscularly with the DNA vaccine : a eukaryotic expression vector (pcDNA1::MOMP) expressing the major outer membrane protein (MOMP) of an avian C. psittaci serovar D strain. Over a period of 11 weeks, cellular uptake of the DNA vaccine was examined by PCR, transcription of the insert by reverse transcript-PCR (RT-PCR) and mRNA translation by immunofluorescence staining of muscle biopsies. RESULTS The results indicate that the DNA vaccine persists in turkey muscle for at least 10 weeks. Moreover, during this period of time MOMP was continuously expressed, as evidenced by the immunofluorescence staining and RT-PCR. CONCLUSION Since C. psittaci infections occur at the age of 3 to 6 and 8 to 12 weeks, a vaccine persistence of 10 weeks seems adequate. Therefore, further research should concentrate on improving the elicited immune response, more specifically the cell-mediated immune response, rather than prolonging the lifespan of the plasmid.
Collapse
Affiliation(s)
- Karolien Loots
- Division of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, Catholic University Leuven, Kasteelpark Arenberg 30, 3001 Leuven, Belgium
| | - Bart Vleugels
- Division of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, Catholic University Leuven, Kasteelpark Arenberg 30, 3001 Leuven, Belgium
| | - Ellen Ons
- Division of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, Catholic University Leuven, Kasteelpark Arenberg 30, 3001 Leuven, Belgium
| | - Daisy Vanrompay
- Department of Molecular Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium
| | - Bruno Maria Goddeeris
- Division of Gene Technology, Department of Biosystems, Faculty of Bioscience Engineering, Catholic University Leuven, Kasteelpark Arenberg 30, 3001 Leuven, Belgium
- Laboratory of Veterinary Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium
| |
Collapse
|
23
|
Cox E, Verdonck F, Vanrompay D, Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 2006; 37:511-39. [PMID: 16611561 DOI: 10.1051/vetres:2006014] [Citation(s) in RCA: 101] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2005] [Accepted: 01/10/2006] [Indexed: 12/21/2022] Open
Abstract
In developing veterinary mucosal vaccines and vaccination strategies, mucosal adjuvants are one of the key players for inducing protective immune responses. Most of the mucosal adjuvants seem to exert their effect via binding to a receptor/or target cells and these properties were used to classify the mucosal adjuvants reviewed in the present paper: (1) ganglioside receptor-binding toxins (cholera toxin, LT enterotoxin, their B subunits and mutants); (2) surface immunoglobulin binding complex CTA1-DD; (3) TLR4 binding lipopolysaccharide; (4) TLR2-binding muramyl dipeptide; (5) Mannose receptor-binding mannan; (6) Dectin-1-binding ss 1,3/1,6 glucans; (7) TLR9-binding CpG-oligodeoxynucleotides; (8) Cytokines and chemokines; (9) Antigen-presenting cell targeting ISCOMATRIX and ISCOM. In addition, attention is given to two adjuvants able to prime the mucosal immune system following a systemic immunization, namely 1alpha, 25(OH)2D3 and cholera toxin.
Collapse
Affiliation(s)
- Eric Cox
- Laboratory of Immunology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
| | | | | | | |
Collapse
|